The FDA recently granted pre-market approval to Prostate Health Index (phi), a noninvasive blood test that manufacturer Beckman Coulter, Inc. claims is 2.5 times more specific in detecting prostate cancer than PSA in patients with PSA values in the 4.0 to 10.0 ng/mL range.
The FDA recently granted pre-market approval to Prostate Health Index (phi), a noninvasive blood test that manufacturer Beckman Coulter, Inc. claims is 2.5 times more specific in detecting prostate cancer than PSA in patients with PSA values in the 4.0 to 10.0 ng/mL range.
"Prostate Health Index is a better test because it provides more accurate information physicians and patients need for better decision making," said William Catalona, MD, of Northwestern University, Chicago. "Now, patients and physicians wondering what to do with an elevated PSA test result in the 4.0 to 10.0 ng/mL range have a new, noninvasive option. This represents an advance in the science of prostate cancer management."
The phi test is indicated for use in men with a PSA in the range of 4.0 to 10.0 ng/mL, and helps physicians distinguish prostate cancer from benign conditions. The results of phi’s multicenter clinical study showed a 31% reduction in unnecessary biopsies, according to Beckman Coulter.
The test will be available in the United States in the third quarter of 2012 for use on the company’s Access 2 and UniCel DxI immunoassay systems.
Dr. Catalona is a consultant/adviser, investigator, and meeting participant/lecturer for Beckman Coulter.
Go back to this issue of Urology Times eNews.
Related Content
Janssen submits supplemental applications for prostate cancer therapy
Investigational prostate Ca agent significantly increases survival
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.